An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557 · readout in 1,293 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Austrian Breast & Colorectal Cancer Study Group.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

5,511actual

Sites

661

Countries

Argentina, Australia, Austria +41

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-10-05

actual

When the study began enrolling

Primary completion

2030-03-04

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2037-05-06

estimated

The whole study's end, after follow-up

First posted

2023-07-19

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Breast Cancer, Early Breast Cancer

Interventions

Drug: Camizestrant — also filed as AZD9833
Drug: Tamoxifen
Drug: Anastrozole
Drug: Letrozole
Drug: Exemestane
Drug: Abemaciclib

Primary outcome

what the primary-completion date above is the date OF

Invasive breast cancer-free survival (IBCFS)

measured Up to 14 years

Publications

PMID 40017004 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed